



EUROBONET
RESEARCH LINE 4, Annual Meeting
HELSINKI, 9-10 July 2009

The program:

Wednesday, July 8th:

20:00 dinner for those already arrived, the restaurant Juuri, Korkeauorenkatu 7

Thursday July 9th

09.00-09.30 Coffee and welcome speech (P. Picci)
Translation of Eurobonet RL4 results to clinical applications (P.C.W. Hogendoorn)

Session 1

09.30-10.30 Report WP 1 (E. De Alava)
10.30-11.30 Report WP 2 (A. Lankester)
11.30-12.30 Report WP 3 (K. Scotlandi)

12.30-13.30 Lunch

Session 2 WP 1: Biology (Chairman E. De Alava)

13.30-15.00

- Molecular diagnosis of EWS/PNET in original tumors and xenografts, Llombart-Bosch A.
- Molecular events in the angiogenesis initiation of human sarcomas Llombart-Bosch, A. et al.
- Evaluation of the side-population in Ewing Sarcoma. Dirksen et al.
- Zebrafish model to study solid tumor invasion. Szuhai et al.
- The Role of Ewing's Tumour Cells in Pathological Bone Resorption. Taylor et al.
- Hypoxia, Glucose-Deprivation and Hypoxia-Inducible Factor: phenotypic effects in Ewing's sarcoma. Knowles et al.
- Discussion.

15.00-15.30 Coffee

Session 3 WP 2: Immunotherapy (Chairman A. Lankester)

15.30-17.00

- Chemo-resistant Ewing sarcoma are susceptible to IL15-activated NK cells which can be modulated by histone deacetylase inhibitors. D. Berghuis, D.H.J. Verhoeven, S. Santos, J. van Kesteren, E.P. Buddingh, K.L. Schaefer, K.Scotlandi, R.M. Egeler, M.W. Schilham, P.C.W. Hogendoorn, A.C. Lankester.
- Differential activation of NK cells and dendritic cells in response to Ewing sarcoma cell lines. J.H.W. Pahl, M.W. Schilham, A.C. Lankester.

- Expression of CXCL12 and its receptor CXCR4/CXCR7 in Ewing sarcoma family of tumors: correlation with histological and clinical response. S. Savola, D. Berghuis, S.J. Santos, M. Schilham, K. Scotlandi, P. Hogendoorn, S. Knuutila, J. Vakkila, A. Lankester.
- Pro-inflammatory chemokine expression in Ewing sarcoma tumors correlates with tumor infiltrating CD3+CD8+ T cell numbers and predict survival. D. Berghuis, S.J. Santos, J.J. Baelde, E.P. Buddingh, M.W. Schilham, P.C.W. Hogendoorn, A.C. Lankester.
- Discussion

17.00-18.00 Guest talk: Novel Molecular Profiling Technologies in Cancer Research (Outi Monni, Helsinki)

19.00-20.45 Reception and sea cruise on M/S Tuulispää, departure from the Market Square
 21.00- Dinner, the restaurant Walhalla, Suomenlinna

Friday July 10th

09.00-09.30 Coffee

Session 4 WP 3: Prognostic markers and targeted therapies (Chairman K. Scotlandi)
 09.30-11.00

- Clinical relevance of copy number alterations in Ewing Sarcoma: Gain of 1q correlates with poor survival and is related with transcriptional patterns of stemness and cell cycle deregulation. Mackintosh et al
- Associations between Wnt-beta catenin signaling and prognosis in Ewing's sarcoma M. C. Manara, M. Sciandra, C. Garofalo, C. Guerzoni, S. Knuutila, A. Llombart-Bosch, P. Picci, K. Scotlandi.
- IGF-IR clathrin/caveolin-dependent endocytosis affects Ewing sarcoma signaling, Ana Sofia Martins et al.
- Targeting insulin-like growth factor-I receptor in Ewing's sarcoma: preclinical results obtained with the hAb Ave1642 and genetic mechanisms of resistance. C. Garofalo, M.C. Manara, G. Nicoletti, S. Knuutila, P. Picci, K. Scotlandi.
- The new dual PI3K/mTOR inhibitor NVP-BEZ235 as a new therapeutic option for sarcomas. S. Ventura, M.C. Manara, G. Nicoletti, L. Landuzzi, P.L. Lollini, S-M. Maira, C. Garcia-Echevarria, C. Garofalo, C. Guerzoni, P. Picci, K. Scotlandi.
- Discussion

11.00-12.30 General conclusions and future plans and collaborations (P. Picci)
 How to proceed after EuroBoNeT or how to draft an "EuroBoNeT 2" (P.C.W. Hogendoorn)

12.30-13.30 Lunch and departure